Medidata opens access to its Patient Insights Program, enabling research organizations to leverage the Patient Centricity by Design process to plan clinical trials
Meditate, a subsidiary of Dassault Systèmes, announced that it is enabling research organizations and CROs (contract research organizations) to leverage its Patient Centricity by Design process for clinical trials. Medidata will open access toPatient Insights Program As part of a new proposal to integrate a patient-centered approach to the design and development of protocols and technologies of clinical trials.
The Patient Insights Program provides access to Medidata's experienced and diverse Patient Insights Board. This approach, through innovative design workshops (Patient Design Studios), is designed to guide the creation of protocols and solutions for patients to improve clinical trial experiences, accelerate clinical trial completion schedules and bring treatments to market faster.
"Medidata is the first company to implement a formal process of bringing the patient perspective into the software development lifecycle to create technical solutions that improve the overall patient experience," said Alicia Staley, Vice President, Patient Engagement at Medidata. "We are giving access to this program to ultimately make clinical trials an option for more people, including those who have historically been left out of clinical trials."
"Patient centricity" has been a thing for almost a decade, but most clinical studies are designed with little or no direct input from the patients/caregivers who are expected to sign up for and stick to a clinical study. Patient engagement was mostly limited to sporadic and superficial encounters, with little effect on reducing patient burden or improving enrollment, persistence, and experience.
"Participating in the Patient Design Studio with Medidata's Patient Companions to create, edit and co-design our Clinical Trial Readiness Tool was invaluable," said Erin Miller, Director of IMPACT Program Development and PATH Program liaison for Lazarex. Cancer Foundation. "This tool is one of a kind, it will help us understand each patient's personal journey and allow us to get them the resources patients need to successfully persist in their clinical trial, and give them hope and a chance for better results in their journey to recovery from cancer."
More of the topic in Hayadan:
